Successful Desensitization of a Patient with Rituximab Hypersensitivity
Rituximab is a monoclonal antibody which targets CD20 in B cells that is used for the treatment of CD20 positive oncologic and hematologic malignancies. Rituximab causes hypersensitivity reactions during infusions. The delay of treatment or loss of a highly efficient drug can be prevented by rapid d...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Case Reports in Immunology |
| Online Access: | http://dx.doi.org/10.1155/2015/524507 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832551602891784192 |
|---|---|
| author | Pinar Ataca Erden Atilla Resat Kendir Sevim Bavbek Muhit Ozcan |
| author_facet | Pinar Ataca Erden Atilla Resat Kendir Sevim Bavbek Muhit Ozcan |
| author_sort | Pinar Ataca |
| collection | DOAJ |
| description | Rituximab is a monoclonal antibody which targets CD20 in B cells that is used for the treatment of CD20 positive oncologic and hematologic malignancies. Rituximab causes hypersensitivity reactions during infusions. The delay of treatment or loss of a highly efficient drug can be prevented by rapid drug desensitization method in patients who are allergic to rituximab. We report a low grade B cell non-Hodgkin lymphoma patient with rituximab hypersensitivity successfully treated with rapid drug desensitization. In experienced centers, drug desensitization is a novel modality to break through in case of hypersensitivity that should be considered. |
| format | Article |
| id | doaj-art-4336bd40f4314acfb8010f00e3eba9b4 |
| institution | Kabale University |
| issn | 2090-6609 2090-6617 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Immunology |
| spelling | doaj-art-4336bd40f4314acfb8010f00e3eba9b42025-02-03T06:00:57ZengWileyCase Reports in Immunology2090-66092090-66172015-01-01201510.1155/2015/524507524507Successful Desensitization of a Patient with Rituximab HypersensitivityPinar Ataca0Erden Atilla1Resat Kendir2Sevim Bavbek3Muhit Ozcan4Department of Hematology, Ankara University, Cebeci, 06590 Ankara, TurkeyDepartment of Hematology, Ankara University, Cebeci, 06590 Ankara, TurkeyDepartment of Pulmonary Medicine, Immunology and Allergy Clinic, Ankara University, Cebeci, 06590 Ankara, TurkeyDepartment of Pulmonary Medicine, Immunology and Allergy Clinic, Ankara University, Cebeci, 06590 Ankara, TurkeyDepartment of Hematology, Ankara University, Cebeci, 06590 Ankara, TurkeyRituximab is a monoclonal antibody which targets CD20 in B cells that is used for the treatment of CD20 positive oncologic and hematologic malignancies. Rituximab causes hypersensitivity reactions during infusions. The delay of treatment or loss of a highly efficient drug can be prevented by rapid drug desensitization method in patients who are allergic to rituximab. We report a low grade B cell non-Hodgkin lymphoma patient with rituximab hypersensitivity successfully treated with rapid drug desensitization. In experienced centers, drug desensitization is a novel modality to break through in case of hypersensitivity that should be considered.http://dx.doi.org/10.1155/2015/524507 |
| spellingShingle | Pinar Ataca Erden Atilla Resat Kendir Sevim Bavbek Muhit Ozcan Successful Desensitization of a Patient with Rituximab Hypersensitivity Case Reports in Immunology |
| title | Successful Desensitization of a Patient with Rituximab Hypersensitivity |
| title_full | Successful Desensitization of a Patient with Rituximab Hypersensitivity |
| title_fullStr | Successful Desensitization of a Patient with Rituximab Hypersensitivity |
| title_full_unstemmed | Successful Desensitization of a Patient with Rituximab Hypersensitivity |
| title_short | Successful Desensitization of a Patient with Rituximab Hypersensitivity |
| title_sort | successful desensitization of a patient with rituximab hypersensitivity |
| url | http://dx.doi.org/10.1155/2015/524507 |
| work_keys_str_mv | AT pinarataca successfuldesensitizationofapatientwithrituximabhypersensitivity AT erdenatilla successfuldesensitizationofapatientwithrituximabhypersensitivity AT resatkendir successfuldesensitizationofapatientwithrituximabhypersensitivity AT sevimbavbek successfuldesensitizationofapatientwithrituximabhypersensitivity AT muhitozcan successfuldesensitizationofapatientwithrituximabhypersensitivity |